Zion Market Research Liquid Biopsy Market, 2016–2024 | Page 4

Liquid Biopsy Market
cancer, leukemia, prostate cancer and other. The end user segment is segregated as hospitals, cancer institutes, diagnostic centers, and academic institutes.
Global Liquid Biopsy Market: Regional Analysis
Geographically, the global liquid biopsy market spread across North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa. North America is expected to have major growth in the global liquid biopsy market owing to a high number of clinical development projects, accessibility, availability and high presence of advanced technologies in diagnostics such as PCR and NGS. In addition, growing prevalence of cancer in this region may foster the global market growth. In Europe, the global liquid biopsy market is also anticipated to witness favorable growth in coming years due to rising cases of lung cancer. In Asia-Pacific, the global market will witness ample growth in future due to the large presence of population, old ages patients, and implementation of advanced healthcare practices.
Global Liquid Biopsy Market: Competitive Players
Major players in the global liquid biopsy market are Myriad Genetics, Roche, Guardant Health, Inc., Janssen Diagnostics, LLC, and MDxHealth SA. Other players influencing the global market are BIOCEPT, Inc., QIAGEN, Trovagene Inc., Fraunhofer-Gesellschaft, and Natera, Inc.